Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Captor TherapeuticsWAR:CTX +0.53%39 3-Year ROIIC % is 619.13 as of Dec. 2025, which is 111% above its 10-year median of 293.19. GuruFocus rates WAR:CTX with a GF Score™ of 39/100 and a GF Value™ of zł10.10 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,323 Biotechnology companies, Captor Therapeutics ranks better than 91.69% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Captor Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 619.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Captor Therapeutics's 3-Year ROIIC % or its related term are showing as below:
WAR:CTX's 3-Year ROIIC % is ranked better than 91.69% of 1323
companies
in the Biotechnology industry
Industry Median: -4.85
vs WAR:CTX: 619.13
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Captor Therapeutics 3-Year ROIIC % Related Terms
Captor Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Captor Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CTX vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Captor Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Captor Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Captor Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Captor Therapeutics's 3-Year ROIIC % falls into.
Captor Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -43.633 (Dec. 2025) - -40.364 (Dec. 2022) )
/
( 17.543 (Dec. 2025) - 18.071 (Dec. 2022) )
=
-3.269
/
-0.528
=
619.13%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Captor Therapeutics (WAR:CTX) has a 3-Year ROIIC % of 619.13 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Captor Therapeutics and its competitors. This is 111% above median its historical median of 293.19. According to the industry distribution chart, Captor Therapeutics ranks #110 out of 1323 companies in the Biotechnology industry, placing it in the top 8.3%.
Is Captor Therapeutics' 3-Year ROIIC % too high?
Captor Therapeutics' current 3-Year ROIIC % of 619.13 is 111% above median its 10-year median of 293.19. Based on the distribution chart, Captor Therapeutics ranks #110 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Captor Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Captor Therapeutics ranks #110 out of 1323 companies for 3-Year ROIIC %. This places Captor Therapeutics in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Captor Therapeutics and its competitors. Captor Therapeutics's current 3-Year ROIIC % is 619.13, which is 111% above median its own 10-year median of 293.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.10, compared to a current price of zł75.30 — trading 645.5% above its estimated fair value. The current 3-Year ROIIC % is 619.13, which is 111% above median its 10-year median of 293.19. Captor Therapeutics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current 3-Year ROIIC % is 619.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued.
The current stock price of zł75.30 is trading 645.5% above its estimated GF Value™ of zł10.10.
GuruFocus considers Captor Therapeutics to be Significantly Overvalued.
Key valuation signals for WAR:CTX:
3-Year ROIIC %: 619.13 (111% above median its 10-year median of 293.19)
GF Value™: zł10.10 vs. price of zł75.30 (645.5% above fair value)
No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
39GF Score
Get the complete analysis for WAR:CTX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CTX has been successfully added to your 
